PedAM
Pediatric Disease Annotations & Medicines
| Disease | adenocarcinoma |
| Phenotype | C0684249|lung carcinoma |
| Sentences | 4 |
| PubMedID- 23801495 | Recent practice guidelines in oncology and pathology recommend that all advanced and metastatic non-small-cell lung carcinoma with adenocarcinoma histology undergo biomarker testing for epidermal growth factor receptor gene (egfr) mutations and anaplastic lymphoma kinase gene (alk) rearrangements. |
| PubMedID- 23862025 | A series of phase ii and randomised phase iii trials in asia and europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemotherapy and are spared from its side effects. |
| PubMedID- 26521535 | Molecular testing of non-small cell lung carcinomas (nsclcc) with adenocarcinoma features has become commonplace with the development and use of targeted treatments for these malignancies. |
| PubMedID- 24260109 | About 80% of lung cancers (lc), the leading cause of cancer-related death throughout the world, are classified as non-small cell lung carcinoma (nsclc) with adenocarcinoma (ac) and squamous cell carcinoma (scc) the two major subtypes of nsclc. |
Page: 1